Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 501976104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Bain Capital Life Sciences Opportunities III, LP 13G/A Amendment 2 | 4.8% |
8/14/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G | 5.1% |
7/29/2026
Event 6/30/2026
|
|
|
Northpond Ventures III, LP
13G/A
Amendment 1
|
6.1% |
2/17/2026
Event 12/31/2025
|
|
| Northpond Ventures III, LP | 4.9% | ||
| Northpond Ventures III GP, LLC | 4.9% | ||
| Northpond Ventures, LP | 0.8% | ||
| Northpond Ventures GP, LLC | 0.8% | ||
| NPV Listed, LLC | 0.4% | ||
| Northpond Ventures, LLC | 0.4% | ||
| Michael P. Rubin | 6.1% | ||
| Bain Capital Life Sciences Opportunities III, LP 13G/A Amendment 1 | 5.4% |
2/17/2026
Event 12/31/2025
|
|
|
Westlake BioPartners Fund I, L.P.
13G/A
Amendment 1
|
7.8% |
2/6/2026
Event 12/31/2025
|
|
| Westlake BioPartners Fund I, L.P. ("Westlake Fund I") | 6.3% | ||
| Westlake BioPartners GP I, LLC ("Westlake GP I") | 6.3% | ||
| Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I") | 1.5% | ||
| Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I") | 1.5% | ||
| Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% | ||
|
GordonMD Global Investments LP
13G
|
7.0% |
11/17/2025
Event 11/13/2025
|
|
| GordonMD Global Investments LP | 7.0% | ||
| GordonMD Long Biased Master Fund LP | 6.2% | ||
| GordonMD Long Biased GP LLC | 6.2% | ||
| Craig D. Gordon | 7.0% | ||
| GordonMD Global Investments GP LLC | 7.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 583 | $3.97 k |
| 2026 Q2 | 128 | 37.6 M | $336 M |
| 2026 Q1 | 116 | 34.8 M | $301 M |
| 2025 Q4 | 105 | 34.1 M | $321 M |
| 2025 Q3 | 79 | 22.7 M | $136 M |
| 2025 Q2 | 83 | 23.2 M | $71.4 M |
| 2025 Q1 | 90 | 25.8 M | $50.0 M |
| 2024 Q4 | 93 | 28.9 M | $108 M |
| 2024 Q3 | 98 | 30.5 M | $150 M |
| 2024 Q2 | 93 | 34.1 M | $256 M |
| 2024 Q1 | 99 | 31.8 M | $789 M |